PE20091359A1 - Proceso de preparacion de compuestos organicos intermediarios de inhibidores de renina - Google Patents

Proceso de preparacion de compuestos organicos intermediarios de inhibidores de renina

Info

Publication number
PE20091359A1
PE20091359A1 PE2009000932A PE2009000932A PE20091359A1 PE 20091359 A1 PE20091359 A1 PE 20091359A1 PE 2009000932 A PE2009000932 A PE 2009000932A PE 2009000932 A PE2009000932 A PE 2009000932A PE 20091359 A1 PE20091359 A1 PE 20091359A1
Authority
PE
Peru
Prior art keywords
preparation
organic compounds
renin inhibitors
alkyl
intermediary
Prior art date
Application number
PE2009000932A
Other languages
English (en)
Inventor
Stuart John Mickel
Gottfried Sedelmeier
Hans Hirt
Frank Schafer
Michael Foulkes
Walter Prikoszovich
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20091359A1 publication Critical patent/PE20091359A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

REFERIDA A UN PROCEDIMIENTO PARA LA FABRICACION DE UN COMPUESTO DE FORMULA (IVa) QUE COMPRENDE REMOVER LOS GRUPOS PROTECTORES R2 Y PG DE UN COMPUESTO DE FORMULA (I), DONDE R ES H, ALQUILO C1-C20 O ALCOXIALQUILO C1-C20; R1 ES H, ALQUILO C1-C20, ALCOXIALQUILO C1-C20; R3 ES H O ALQUILO C1-C20; R2 ES H O HIDROXILO; PG ES UN GRUPO PROTECTOR AMINO TAL COMO UN ALCOXICARBONILO C1-C7. DICHOS COMPUESTOS SON UTILES COMO INTERMEDIARIOS EN LA PREPARACION DE COMPUESTOS INHIBIDORES DE RENINA TALES COMO EL ALISCIREN
PE2009000932A 2005-06-08 2006-06-06 Proceso de preparacion de compuestos organicos intermediarios de inhibidores de renina PE20091359A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0511686.8A GB0511686D0 (en) 2005-06-08 2005-06-08 Organic compounds

Publications (1)

Publication Number Publication Date
PE20091359A1 true PE20091359A1 (es) 2009-10-13

Family

ID=34835327

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2006000621A PE20070075A1 (es) 2005-06-08 2006-06-06 Procedimiento de preparacion para compuestos inhibidores de renina
PE2009000932A PE20091359A1 (es) 2005-06-08 2006-06-06 Proceso de preparacion de compuestos organicos intermediarios de inhibidores de renina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2006000621A PE20070075A1 (es) 2005-06-08 2006-06-06 Procedimiento de preparacion para compuestos inhibidores de renina

Country Status (24)

Country Link
US (2) US7767831B2 (es)
EP (2) EP2080754A3 (es)
JP (2) JP2008542415A (es)
KR (1) KR20080014011A (es)
CN (1) CN101193860B (es)
AR (1) AR054374A1 (es)
AU (1) AU2006256938B2 (es)
BR (1) BRPI0611919A2 (es)
CA (1) CA2608575A1 (es)
EC (1) ECSP077986A (es)
GB (1) GB0511686D0 (es)
GT (1) GT200600208A (es)
IL (1) IL187004A0 (es)
MA (1) MA29563B1 (es)
MX (1) MX2007015418A (es)
NO (1) NO20080080L (es)
NZ (2) NZ562889A (es)
PE (2) PE20070075A1 (es)
RU (1) RU2418785C2 (es)
SG (1) SG155209A1 (es)
TN (1) TNSN07465A1 (es)
TW (1) TW200716544A (es)
WO (1) WO2006131304A2 (es)
ZA (1) ZA200709076B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0521083D0 (en) * 2005-10-17 2005-11-23 Novartis Ag Organic compounds
DE102007049039A1 (de) 2007-10-11 2009-04-16 Reuter Chemischer Apparatebau Kg Verfahren zur Herstellung von 8-Hydrazino-8-Aryl-Octanoylderivaten und deren Verwendung
EP2062874B1 (en) 2007-11-20 2014-12-17 KRKA, tovarna zdravil, d.d., Novo mesto Process and intermediates for the preparation of aliskiren
EP2225200B1 (en) * 2007-12-24 2013-10-16 DSM IP Assets B.V. Convergent synthesis of renin inhibitors and intermediates useful therein
SI2189442T1 (sl) 2008-11-20 2015-03-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Postopek in intermediati za pripravo aliskirena
WO2011019789A1 (en) * 2009-08-11 2011-02-17 Novartis Ag The ring opening of lactones and lactams
WO2011051853A1 (en) 2009-10-29 2011-05-05 CarboDesign LLC Manufacturing process for preparing enaniomerically pure 8- aryloctanoic acid derivatives such as aliskiren
WO2011098258A1 (en) * 2010-02-10 2011-08-18 Ratiopharm Gmbh Salts of aliskiren
US8703976B2 (en) 2011-10-02 2014-04-22 Milan Soukup Manufacturing process for 8-aryloctanoic acids such as Aliskiren
CN111423325A (zh) * 2020-04-26 2020-07-17 江苏凯迪恩医药科技有限公司 基于蒽醌类药物的双醋瑞因合成方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4570108A (en) * 1982-07-06 1986-02-11 Stroede Aake Protection device for electrical incandescent lamps
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
US5606078A (en) 1994-04-18 1997-02-25 Ciba-Geigy Corporation 3,5-Disubstituted tetrahydrofuran-2-ones
US5659065A (en) 1994-04-18 1997-08-19 Novartis Corporation Alpha-aminoalkanoic acids and reduction products
CA2121898A1 (en) * 1994-04-21 1995-10-22 Stephen Hanessian Synthesis of prototypes for renin inhibitors
JP2005231999A (ja) * 2000-03-08 2005-09-02 Banyu Pharmaceut Co Ltd カルバペネム誘導体の製造方法
DE60138099D1 (de) 2000-07-05 2009-05-07 Speedel Pharma Ag Verfahren zur herstellung von substituierten octanoyl-amiden
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
DE60123911T2 (de) * 2000-12-14 2007-05-31 Speedel Pharma Ag Verfahren zur Herstellung von Aryloctanoyl-amiden
GB0419361D0 (en) * 2004-08-31 2004-10-06 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
MX2007015418A (es) 2008-02-21
PE20070075A1 (es) 2007-03-16
GT200600208A (es) 2007-03-28
WO2006131304A2 (en) 2006-12-14
EP2080754A2 (en) 2009-07-22
GB0511686D0 (en) 2005-07-13
RU2007148226A (ru) 2009-07-20
AU2006256938A1 (en) 2006-12-14
CA2608575A1 (en) 2006-12-14
CN101193860A (zh) 2008-06-04
EP1896411A2 (en) 2008-03-12
MA29563B1 (fr) 2008-06-02
JP2013028607A (ja) 2013-02-07
NZ591010A (en) 2012-06-29
IL187004A0 (en) 2008-02-09
BRPI0611919A2 (pt) 2010-10-05
AU2006256938B2 (en) 2009-12-17
JP2008542415A (ja) 2008-11-27
SG155209A1 (en) 2009-09-30
US7767831B2 (en) 2010-08-03
RU2418785C2 (ru) 2011-05-20
EP2080754A3 (en) 2010-06-02
TW200716544A (en) 2007-05-01
NO20080080L (no) 2008-01-04
WO2006131304A3 (en) 2007-07-19
US20100274027A1 (en) 2010-10-28
KR20080014011A (ko) 2008-02-13
TNSN07465A1 (en) 2009-03-17
CN101193860B (zh) 2013-01-02
NZ562889A (en) 2011-11-25
ZA200709076B (en) 2008-10-29
ECSP077986A (es) 2008-01-23
US20080207921A1 (en) 2008-08-28
AR054374A1 (es) 2007-06-20

Similar Documents

Publication Publication Date Title
PE20091359A1 (es) Proceso de preparacion de compuestos organicos intermediarios de inhibidores de renina
ES2530991T3 (es) Procedimiento para la obtención de betamiméticos
ECSP10010405A (es) Procesos e intermediarios para la preparacion de derivados de acido 5-bifenil-4-il-2-metilpentanoico
UA109883C2 (uk) Спосіб отримання сполук для застосування як інгібіторів sglt2
MX2009003834A (es) Derivados de pirrolidina como inhibidores de iap.
GT200500223A (es) Polimorfo ii de rapamicina y sus utilizaciones
PA8676301A1 (es) Metodos para sintetizar derivados de 6-alquilaminoquinolina
CL2019002919A1 (es) Compuestos inhibidores vmat2 y composiciones relacionadas.
BR122019015876B8 (pt) compostos derivados de 1,2,5-oxadiazóis, composição, bem como seus usos
CR9244A (es) AMINO-IMIDAZOLONAS PARA LA INHIBICION DE ß-SECRETASA
MY150596A (en) Hsp90 inhibitors
UA108378C2 (uk) Спосіб одержання плеуромутилінів
ECSP11010830A (es) Derivados de heteroarilo como inhibidores de dgat1
PT2421879E (pt) Novos 7-deazapurina nucleósidos para utilizações terapêuticas
PE20060583A1 (es) Tiazolil-dihidro-indazoles como inhibidores de pi3-quinasas
PE20040956A1 (es) Procedimiento para preparar la sal 5-[(r)-2-(5,6-dietil-indan-2-ilamino)-1-hidroxi-etil]-8-hidroxi-(1h)-quinolin-2-ona
NI201000049A (es) Método para producir 2'-desoxi-5-azacitidina (decitabina)
UY32077A (es) Inhibidores de quinasa tipo polo
BR112019005294A2 (pt) processo para preparar (±)-2-exo-(2-metilbenzilóxi)-1-metil-4-isopropil-7-oxabiciclo[2.2.1]heptano de fórmula (i) e método para prevenir ou reduzir a formação de depósitos no interior de um reator
EA200970266A1 (ru) Азабициклические соединения в качестве ингибиторов повторного поглощения моноаминов
AR108558A2 (es) Método para preparar ácido (+)-1,4-dihidro-7-[(3s,4s)-3-metoxi-4-(metilamino)-1-pirrolidinil]-4-oxo-1-(2-tiazolil)-1,8-naftiridin-3-carboxílico
EA201290872A1 (ru) Способ получения бензоксаборолов
ECSP099315A (es) Inhibidores de cinasa
PE20070526A1 (es) Metodos para preparar derivados de acido glutamico
UA85701C2 (ru) Способ получения ингибиторов триптазы

Legal Events

Date Code Title Description
FD Application declared void or lapsed